Abstract: There is provided a tissue scaffold and a method for making a tissue scaffold. The tissue scaffold comprises elastin and optionally fibrin and/or collagen. The elastin in the scaffold may be cross-linked. The elastin that is cross-linked preferably comprises solubilised elastin and is unfractionated.

Abstract: Microorganisms and bioprocesses are provided that convert gaseous C1 containing substrates, such as syngas, producer gas, and renewable H2 combined with CO2, into nutritional and other useful bioproducts.

Abstract: The present disclosure provides an endophyte, Serendipita vermifera ssp. bescii (“S. bescii”), uses thereof and methods incorporating the use thereof for enhancement of plant performance, particularly the use of S. bescii with phosphite as a phosphorous source. The present disclosure also provides methods for detecting the presence of and identifying S. bescii.

Abstract: The present disclosure relates generally to detection of molecular biomarkers in a sample or diagnosis of a subject based upon detection or quantification of molecular biomarkers in a sample, specifically to the identification and use of biomarkers for pancreatic cysts.

Abstract: A method of treating a mammal with one of a central nervous system injury and a neurodegenerative disorder comprising isolating, culturing, and generating neural progenitor cells from a mammalian placenta, and transplanting the placenta derived neural progenitor cells into a brain of the mammal.

Abstract: A human dietary supplement comprises theacrine and optionally other compounds that modulate the effects of theacrine. Uses for the theacrine-containing supplement include improvement of at least one of mood, energy, focus, concentration or sexual desire or a reduction of at least one of anxiety or fatigue. A synergistic composition comprises co-administration of theacrine and caffeine, wherein the co-administered caffeine reduces theacrine oral clearance (CL/F) and oral volume of distribution (Vd/F). In addition, the co-administered caffeine increases area under the plasma concentration time curve (AUC) of theacrine, and increases theacrine maximum plasma concentration (Cmax) in comparison with the corresponding pharmacokinetic parameters when theacrine is administered alone.

Abstract: A liquid sporulation method is described. A first liquid culture is prepared by adding bacterial cells to a sporulation broth, wherein an optical density (OD600) of the first liquid culture is in a range of 0.001 to 0.01. The first liquid culture is incubated and an optical density (OD600) thereof is increased to be in a range of 0.2 to 2.0. Second liquid culture is prepared by adding the incubated first liquid culture to a predetermined amount of additional sporulation broth, wherein an optical density (OD600) of the second liquid culture is in the range of 0.001 to 0.1, and a ratio of a volume of the second liquid culture to a volume of the first liquid culture is in a range of 10:1 to 150:1. The second liquid culture is incubated so an optical density (OD600) thereof is increased to be in a range of 1.0 to 4.0.

Abstract: The present invention relates to strains of Penicillium camemberti and to the use thereof for the preparation of food products, for example of dairy and/or vegetable origin, such as the ripening of soft cheeses having a moldy and/or mixed crust, in particular camembert.

Abstract: The present disclosure is directed to methods of treating a steatosis-associated disorder by administering a therapeutic agent selected from a lysosomal enzyme, an autophagy-inducing agent, or a combination thereof. Steatosis-associated disorders discussed herein include GSD Ia, GSD Ib, GSD Ic, NAFLD, and NASH. Other embodiments are directed to methods of reversing steatosis, modulating autophagy, inducing autophagy, and reversing glycogen storage.

Abstract: Embodiments of the disclosure include particular amyloglucosidase (AMG) compositions formulated as a nutriceutical or medicinal food, for example. The AMG compositions are formulated at a specific dosage and/or are lacking in one or more toxins or have substantially reduced levels of toxin, such as deoxynivalenol (vomit toxin). The AMG compositions are provided to individuals in need thereof, such as an individual with or at risk for congenital sucrase isomaltase syndrome, functional bowel disorders, small bowel bacterial overgrowth, protein-calorie malnutrition (marasmus), radiochemotherapy-induced mucositis and/or short-gut syndrome.

Abstract: The present invention provides a method, wherein the method forms a biofilm, wherein the biofilm comprises a population of at least one bacterial strain attached to particles, wherein the biofilm is configured to colonize a gut of a subject in need thereof for at least five days, when ingested by the subject, the method comprising: a. obtaining a population comprising at least one strain of bacteria; b. inoculating a growth medium containing particles with the population comprising at least one strain of bacteria; c. incubating the particles with the population comprising at least one bacterial strain for a time sufficient for the population of at least one strain of bacteria to attach to the particles; and d. culturing the population comprising at least one strain of bacteria attached to the particles in a growth medium, for a time sufficient to form a biofilm.

Abstract: The present invention relates to a pharmaceutical composition, a food composition, and a food additive for the prevention and treatment or improvement of muscle loss, muscle weakness, and muscle atrophy, which contain Enterococcus faecalis, particularly Enterococcus faecalis EF-2001 among others, a culture solution thereof, or a killed body thereof as an active ingredient. Killed Enterococcus faecalis EF-2001 of the present invention exhibits a remarkable treatment effect for muscle loss, muscle weakness, and muscle atrophy by inhibiting the damage to muscle cells induced by oxidative stress, and thus killed lactic acid bacterium Enterococcus faecalis EF-2001 of the present invention or a culture solution thereof can be usefully used as an active ingredient in a pharmaceutical composition, a food composition, and a food additive for prevention of muscle atrophy and sarcopenia.

Abstract: Some embodiments include bacterial species for use in treatment of one or more autism spectrum disorder (ASD), and/or schizophrenia symptoms in a subject in need thereof. The subject in need thereof can have a gut microbiota signature characteristic of an adult. The bacterial species can include Bacteroides (e.g., B. fragilis, B. thetaiotaomicron, and/or B. vulgatus), and/or Enterococcus (e.g., E. faecalis, E. faecium, E. hirae, E. avium, E. durans, E. gallinarum, or E. casseliflavus). Upon treatment, one or more ASD-related behaviors can be improved in the subject.

Abstract: The present invention relates to a starter culture comprising at least two Streptococcus thermophilus strains, wherein a first and a second Streptococcus thermophilus strain are chosen from RGP group 1, RGP group 2, RGP group 3 and RGP group 4, with the proviso that the first and second Streptococcus thermophilus strains do not belong to the same RGP group.

Abstract: One aspect of the present disclosure can include a method for reducing or alleviating inflammation in the digestive tract of a subject in need thereof that consumes a disruptive dietary component. One step of the method can include assaying a previously obtained fecal sample from the subject for the presence of one or more Proteobacteria and an activity level of a peroxidase enzyme. The subject can decrease ingestion of the disruptive dietary component if the assayed presence of the one or more Proteobacteria and the activity level of the peroxidase enzyme are increased as compared to control levels.

Abstract: Described herein are compositions, methods, kits and devices for the treatment and/or prevention of a wide spectrum of disease conditions. In particular, bacterial populations described herein are live, purified bacteria for the modulation, restoration and/or promotion of the microbiome in the upper respiratory tract of a subject, including the nasal cavity, to promote health. Such bacterial populations may include single or multiple strains for bacteria. The multiple strains of bacteria may be strains from the same or different species, including species of Corynebacterium and/or Dolosigranulum pigrum.

Abstract: Methods and kits for treating a cardiac arrhythmia using a platelet rich plasma (PRP) composition are provided. Any type of arrhythmia may be treated using the PRP composition. The PRP composition may comprise PRP developed using blood collected from a patient suffering the cardiac arrhythmia. The PRP composition may be buffered to a physiological pH and may include one or more anti-arrhythmic agents, anti-coagulants, or other drugs. The PRP composition may be delivered using a nebulizer, minimally invasively, or surgically.

Abstract: Methods are disclosed herein for increasing retinal ganglion cell survival in a subject in need thereof. These methods include selecting a subject in need of increased retinal ganglion cell survival and administering a therapeutically effective amount of isolated nanovesicles derived from an extracellular matrix (MBVs) to the subject.

Abstract: The present invention provides novel methods for poling piezoelectric materials, e.g., collagen, which are carried out in the absence of liquid media and at a relatively low temperature. The present invention also provides electroactive scaffolds comprising poled collagen for promoting cell growth and differentiation.

Abstract: An object is to provide a degrading bacteria-immobilized carrier on which a 1,4-dioxane-degrading bacterium is supported, as well as a biodegradation treatment method for organic compounds, and a biodegradation treatment apparatus, both using this carrier. As a means for achieving the object, a degrading bacteria-immobilized carrier comprising a porous carrier and a 1,4-dioxane-degrading bacterium supported on the porous carrier, as well as a biodegradation treatment method for organic compounds, and a biodegradation treatment apparatus, both using this carrier, are provided.